Table 2.
Summary of correlation of TMEM17 expression with clinicopathological characteristics of invasive breast cancer
| Clinicopathological feature | N | TMEM17
|
χ2 | p-value | |
|---|---|---|---|---|---|
| Negative | Positive | ||||
| All cases | 167 | 40 | 127 | ||
| Age (years) | |||||
| ≤49 | 84 | 23 | 61 | 1.091 | 0.296 |
| >49 | 83 | 17 | 66 | ||
| T-stage | |||||
| T1 + T2 (≤5 cm) | 118 | 34 | 84 | 5.218 | 0.022 |
| T3 + T4 (>5 cm) | 49 | 6 | 43 | ||
| TNM stage | |||||
| I+II | 99 | 31 | 68 | 7.233 | 0.007 |
| III | 68 | 9 | 59 | ||
| Lymph node metastasis | |||||
| Negative | 88 | 28 | 60 | 6.319 | 0.012 |
| Positive | 79 | 12 | 67 | ||
| ER, PR, and Her-2 | |||||
| Non-TNBC | 129 | 30 | 99 | 0.151 | 0.698 |
| TNBC | 38 | 10 | 28 | ||
Abbreviations: TNBC, triple-negative breast cancer; ER, estrogen receptor; PR, progesterone receptor.